Overview

Mass Balance, Pharmacokinetics and Metabolism Study of IXAZOMIB

Status:
Completed
Trial end date:
2016-02-09
Target enrollment:
Participant gender:
Summary
This is a phase 1, 2-part, open-label study in 4 to 6 pharmacokinetic-evaluable participants with advanced solid tumors or lymphoma.
Phase:
Phase 1
Details
Lead Sponsor:
Millennium Pharmaceuticals, Inc.
Treatments:
Glycine
Ixazomib